title: Liposomal amphotericin B can safely be administered in paediatric outpatients with cancer for the primary or secondary prevention of invasive aspergillosis.
authors.forename: Arne
authors.initials: A
authors.lastname: Simon
authors.forename: Udo
authors.initials: U
authors.lastname: Bode
authors.forename: Maria
authors.initials: M
authors.lastname: Maul
authors.forename: Gudrun
authors.initials: G
authors.lastname: Fleischhack
mesh_terms: D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D005260:Female; D018575:Home Care Services, Hospital-Based; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous / Q000451:nursing; D008081:Liposomes; D008297:Male; D009369:Neoplasms / Q000150:complications; D010045:Outpatients
chemical_list: D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B